alexa General Topics in the Field of Personalized Cancer Therapy | Open Access Journals
ISSN: 2153-0769
Metabolomics:Open Access
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

General Topics in the Field of Personalized Cancer Therapy

Lu DY1*, Lu TR1, Xu B2, Ding J2 and Yarla NS3

1Shanghai University, Shanghai 200444, China

2Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

3GITAM University, AP, India

*Corresponding Author:
Lu DY
Shanghai University, Shanghai 200444, China
Tel: +86 21 66163545
Fax: +821 66132177
E-mail: [email protected]

Received date: August 31, 2017; Accepted date: September 01, 2017; Published date: September 06, 2017

Citation: Lu DY, Lu TR, Xu B, Ding J, Yarla NS (2017) General Topics in the Field of Personalized Cancer Therapy. Metabolomics (Los Angel) 7:e001. doi: 10.4172/2153-0769.S1-e001

Copyright: © 2017 Lu DY, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Metabolomics:Open Access

Abstract

Personalized medicine is a new frontier in modern medicine. Personalized cancer therapy (PCT) has been developing over 60 years. But, PCT remains to be improved. Central dogma is waiting for uncovering. This perspective addresses this matter briefly.

Keywords

Personalized cancer therapy; Individualized cancer therapy; Drug sensitivity testing; Cancer biomarker; Pharmacogenomics; Antimetastatic therapy; Drug combination; Assistant chemotherapy

Introduction

PCT is imperfect now due to unsatisfactory clinical outcomes and higher costs in some of the strategies. There are several key factors for these unsatisfactory therapeutic benefits. My early reviews gave a panorama of currently applied PCT strategies, especially the drawback of every PCT (individualized cancer chemotherapy, ICC) strategiesdrug sensitivity testing (DST), cancer biomarkers, bioinformatics, pharmacogenetics (PG), antimetastatic therapy, drug combination, assistant chemotherapy, cost-effective [1-7]. It serves as a platform or vehicle for discussion and promotion of these ICC strategies.

Which Strategy is More Powerful?

DST and PG are the mainstream of current PCT/ICT) [8,9]. By analyzing different available PCT/ICT strategies, we suggest is that no unilateral type of ICC strategies work now. Our argument is based on current clinical practice. DST [10,11] or PG [12-14] is unsatisfactory individually. Patients’ survival has improved very little in spite of utilization of DST [10,11]. Many factors, such as increasing drug number in the DST, development of active and specific anticancer or antimetastatic drugs [15-18], may ameliorate this condition. However, this is not enough in clinics.

Sequencing cancer genomes has gradually increased our capability to pinpoint to tumor biomarkers. Detection of human or cancer genetic, transcript, protein or glycoprotein molecular and bioinformatics need less and less moneys in future. The cancer biomarker or bioinformatics detection-based ICT strategy will also improve with technical innovations in the future [9].

A recent genomic study of >3,000 tumors across 26 cancer types has been underway. Only 1/4 of these tumors contain known cancer genes [8]. It means that most tumors are caused by undefined cancer genes. Thus there is a great potential for further investigations of cancer biomarkers.

Now PCT/ICT can be mainly divided into DST, PG and cancer biomarker detection. In future, new disciplines such as individualized antimetastatic chemotherapy and individualized assistant chemotherapy may soon come into reality. The greatest drawbacks of present individualized cancer chemotherapy are designed to target primary tumors rather than metastatic lesions [15-18], inconvenience, high costs [19,20] and lack of effective antimetastatic drugs [21,22]. Individualized antimetastatic chemotherapy might be the key of future strategy.

In the past, we can see that each ICT/PCT strategy is to narrow to provide information of both tumor characters (pathology) and pharmacology (drug sensitivity). These two patterns of biomedical information are not overlapped. Thus, we are sure that future trend is to introduce integrated ones of PCT/ICT that will provide the information of two.

A lot of hospitals never try of any ICC strategies. In future, ICC strategies should be improved and perfected for survival benefits or even cure of late stage of cancer patients. The more we try different types of ICT strategies in the clinics, the more satisfactory outcome we may obtain. We wish more cancer clinicians notice and apply these strategies because ICC strategies are best ways to treat and cure cancer patients.

The ultimate goal is to markedly decrease death from cancer. To guide therapeutics, ICT/PCT strategies seem to be one of best options for cancer treatment. No matter which type of ICC strategies is used in clinics, it ought to be effective and in reasonable cost. According to this rule, new ICT/PCT strategies might be innovated. In the past 10 years, the focus of ICT/PCT strategies has been transformed from drug sensitivity test into pharmacogenomics. In the next decade, we hypothesize that ICT/PCT strategies will be transformed from DST [10,11] to PG [12-14] to cancer biomarker-oriented therapy or individualized antimetastatic therapy [15-18] and finally combine patho-pharmacology information of all. New era of ICT/PCT is coming, are we ready for that [23,24] ?.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Article Usage

  • Total views: 69
  • [From(publication date):
    October-2017 - Oct 21, 2017]
  • Breakdown by view type
  • HTML page views : 48
  • PDF downloads :21
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords